Erratum: TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis (Theranostics (2019) 9:22 (6676-6689) DOI: 10.7150/thno.34020)

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors wish to inform readers of a correction to the study. The informed consent and the IRB approval number in the Materials and methods section, should be revised as follows: The human tissue biopsy samples used in this study were collected as part of a study approved by the human ethics committee of Taipei Medical University Joint Institutional Review Board (TMU-JIRB No. N201701061). The waiver of informed consent for the study was monitored by TMU-JIRB. The authors regret the inconsistency and apologize for not identifying the issue earlier in the publication process.

Original languageEnglish
Pages (from-to)2079
Number of pages1
JournalTheranostics
Volume11
Issue number5
DOIs
Publication statusPublished - Jan 1 2021

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Fingerprint

Dive into the research topics of 'Erratum: TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis (Theranostics (2019) 9:22 (6676-6689) DOI: 10.7150/thno.34020)'. Together they form a unique fingerprint.

Cite this